GO:1901799 negative regulation of proteasomal protein catabolic process: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1901799 describes any process that stops, prevents, or reduces the frequency, rate, or extent of proteasomal protein catabolic process.
• The term is a biological_process ontology entry and includes synonyms such as inhibition of proteasome-mediated protein catabolism.
• Negative regulation occurs through deubiquitination, altered substrate targeting, and inhibition of proteasome activity or assembly.
• Key regulators include E3 ubiquitin ligases, deubiquitinating enzymes, and proteasome-associated factors that modulate degradation of signaling proteins.
• Dysregulation of this process contributes to cancer, immune disorders, and neurodegenerative diseases by stabilizing or destabilizing critical proteins.
• CRISPR knockout, point mutation, knock-in, and overexpression models enable precise dissection of negative regulation mechanisms.
Description
The Gene Ontology term GO:1901799, negative regulation of proteasomal protein catabolic process, defines any process that stops, prevents, or reduces the frequency, rate, or extent of proteasomal protein catabolic process. This biological_process is essential for maintaining protein homeostasis and controlling the abundance of regulatory proteins that govern cell cycle, apoptosis, immune signaling, and stress responses. Researchers study this term to understand how cells fine-tune protein degradation in health and disease. The proteasome is a large protease complex that degrades ubiquitinated proteins, and its negative regulation can occur at multiple levels, including deubiquitination of substrates, inhibition of proteasome activity, or sequestration of substrates away from the proteasome. Dysregulation of this process has been implicated in cancer, where stabilized oncoproteins or destabilized tumor suppressors drive tumorigenesis. In immunity, negative regulation of proteasomal degradation modulates innate antiviral responses by controlling the stability of signaling adaptors such as MAVS. Thus, GO:1901799 represents a critical node in cellular decision-making and a promising target for therapeutic intervention.
negative regulation of proteasomal protein catabolic process At A Glance
| GO ID | GO:1901799 |
|---|---|
| GO term | negative regulation of proteasomal protein catabolic process |
| Ontology | biological_process |
| Synonym | inhibition of proteasome-mediated protein catabolic process; downregulation of proteasomal protein catabolic process; negative regulation of proteasome-mediated protein catabolism |
| Major function | Stops, prevents, or reduces the frequency, rate, or extent of proteasomal protein catabolic process |
| Related processes | Protein homeostasis, ubiquitin-dependent degradation, signal transduction, immune response, apoptosis |
| Cellular context | Cytoplasm, nucleus, proteasome-associated compartments |
| Research relevance | Cancer, immune disorders, neurodegeneration, plant hormone signaling |
What Is GO:1901799?
GO:1901799 is defined as any process that stops, prevents, or reduces the frequency, rate, or extent of proteasomal protein catabolic process. In other words, it encompasses molecular events that inhibit the degradation of proteins by the proteasome, thereby stabilizing specific substrates and altering downstream signaling or cellular outcomes.
Why Is negative regulation of proteasomal protein catabolic process Important in Cell Biology?
Understanding GO:1901799 is crucial because negative regulation of proteasomal degradation controls the half-life of key regulatory proteins, thereby influencing virtually every cellular process, including cell cycle progression, apoptosis, immune signaling, and stress responses. Dysregulation of this process can lead to the accumulation of oncoproteins or the premature loss of tumor suppressors, contributing to cancer and other diseases. Moreover, pathogens and cancer cells exploit negative regulators to evade immune detection, making these pathways attractive therapeutic targets.
• Controls stability of cell cycle regulators and apoptosis effectors, impacting cancer development.
• Modulates innate immune signaling by regulating degradation of adaptors like MAVS.
• Influences plant hormone signaling, as shown for ABA signaling through AFP1-mediated degradation of ABI5.
• Affects MAPK signaling pathways by altering the turnover of pathway components.
• Plays a role in resistance to CD8+ T cell dysfunction via KLHL6-mediated regulation.
• Involved in ubiquitination-independent degradation of PPM1D, highlighting diverse mechanisms.
• Regulates proteasome assembly and activity in fission yeast, affecting petite-negativity.
• Provides targets for pharmacological intervention in cancer and immune disorders.
What Happens During negative regulation of proteasomal protein catabolic process?
Deubiquitination of Substrates
In simple terms: Enzymes remove ubiquitin tags from proteins, preventing their delivery to the proteasome.
Deubiquitinating enzymes (DUBs) cleave ubiquitin chains from substrate proteins, thereby rescuing them from proteasomal degradation. This is a major mechanism of negative regulation, as exemplified by DUBs that counteract E3 ligase activity and stabilize immune signaling components. For instance, negative regulation of innate immune responses often involves DUBs that remove K48-linked ubiquitin chains from targets like MAVS, preventing their proteasomal turnover.
Inhibition of Proteasome Activity
In simple terms: Certain proteins or molecules can directly block the proteasome's ability to degrade proteins.
Negative regulation can occur through direct inhibition of proteasome catalytic activity or by interfering with proteasome assembly. For example, proteasome regulation in fission yeast involves factors that modulate proteasome function and affect petite-negativity. Additionally, some proteins may bind to the proteasome and inhibit its activity, though specific examples in the context of GO:1901799 are less characterized.
Sequestration of Substrates
In simple terms: Proteins can be held in locations or complexes that prevent them from being degraded.
Substrate sequestration away from the proteasome is another mode of negative regulation. For instance, PPM1D is degraded by proteasomes in a ubiquitination-independent manner through its carboxyl-terminal region, suggesting that accessibility to the proteasome can be regulated. Similarly, interactions with chaperones or scaffolding proteins may mask degradation signals, reducing proteasomal catabolism.
Regulation of E3 Ligase Activity
In simple terms: The enzymes that tag proteins for degradation can themselves be inhibited or degraded.
Negative regulation of proteasomal degradation often involves modulating the activity or abundance of E3 ubiquitin ligases. For example, the E3 ligase ASB3 targets MAVS for degradation, and its downregulation would negatively regulate proteasomal catabolism of MAVS. Conversely, KLHL6, a ubiquitin ligase, drives resistance to CD8+ T cell dysfunction, indicating that its activity can be regulated to affect protein stability. Thus, controlling E3 ligases is a key node in negative regulation.
Ubiquitination-Independent Mechanisms
In simple terms: Some proteins are degraded by the proteasome without being tagged by ubiquitin, and this can be regulated.
PPM1D is directly degraded by proteasomes in a ubiquitination-independent manner through its carboxyl-terminal region, revealing that negative regulation can also target ubiquitin-independent degradation pathways. This expands the scope of GO:1901799 beyond canonical ubiquitin-proteasome system components.
Key Genes Involved in GO:1901799 negative regulation of proteasomal protein catabolic process
The following genes and proteins are key players in negative regulation of proteasomal protein catabolic process, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| KLHL6 | Ubiquitin ligase that drives resistance to CD8+ T cell dysfunction | T cell exhaustion, cancer immunotherapy |
| MAVS | Mitochondrial antiviral signaling adaptor targeted by ASB3 for degradation | Innate immunity, antiviral response |
| ASB3 | E3 ligase that downregulates antiviral innate immunity by targeting MAVS | Host-pathogen interaction, immune evasion |
| PPM1D | Phosphatase degraded by proteasomes in a ubiquitination-independent manner | Cancer, DNA damage response |
| ABI5 | Transcription factor degraded via AFP1 to regulate ABA signaling | Plant hormone signaling, stress response |
| AFP1 | F-box protein that mediates degradation of ABI5 | Plant development, ABA signaling |
| PUB35 | U-box E3 ligase that negatively regulates ABA signaling | Plant stress tolerance |
| DUBs (e.g., USP, OTU family) | Deubiquitinating enzymes that remove ubiquitin from substrates | Immune regulation, cancer |
| Proteasome subunits (e.g., PSMA, PSMB) | Core catalytic components of the proteasome | Protein homeostasis, drug targeting |
| MAPK pathway components | Kinases and scaffolds regulated by ubiquitin-proteasome system | Signal transduction, cancer |
| Apoptosis regulators (e.g., BCL-2 family) | Pro- and anti-apoptotic proteins controlled by degradation | Cell death, cancer therapy |
| KLHL6 substrates | Proteins targeted by KLHL6 for degradation | T cell function |
| PPM1D carboxyl-terminus | Region mediating ubiquitin-independent degradation | Protein engineering, cancer |
| MAVS interactors | Proteins modulating MAVS stability | Antiviral immunity |
| ABA signaling components | ABI5, AFP1, PUB35 network | Plant biology |
| Proteasome assembly chaperones | Proteins assisting proteasome formation | Fission yeast models |
| E3 ligase complexes | Multi-subunit complexes that tag substrates | Drug discovery |
How Is negative regulation of proteasomal protein catabolic process Regulated?
Negative regulation of proteasomal protein catabolic process is itself regulated at multiple levels. Deubiquitinating enzymes (DUBs) counteract E3 ligases, providing a reversible switch for substrate stability. E3 ligase activity can be modulated by phosphorylation, subcellular localization, or auto-ubiquitination. Additionally, proteasome activity can be influenced by associated factors and post-translational modifications of proteasome subunits. In plant ABA signaling, the F-box protein AFP1 mediates degradation of ABI5, and PUB35 negatively regulates this pathway, illustrating layered control. Ubiquitination-independent degradation of PPM1D is regulated by its carboxyl-terminal region, suggesting intrinsic structural determinants. Overall, this process is tightly controlled to maintain proteostasis and respond to cellular cues.
negative regulation of proteasomal protein catabolic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| KLHL6 | T cell dysfunction, cancer immunotherapy | Knockout mice, CAR-T cells |
| MAVS | Antiviral innate immunity | Knockout cell lines, viral infection models |
| PPM1D | Cancer, DNA damage response | Point mutation knock-in, overexpression |
| ABI5 | Plant ABA signaling, drought stress | Arabidopsis knockout, overexpression |
| Proteasome subunits | Neurodegeneration, cancer | Knockout, tagged knock-in |
Cancer
Negative regulation of proteasomal degradation can stabilize oncoproteins or destabilize tumor suppressors, promoting tumorigenesis. For example, KLHL6 drives resistance to CD8+ T cell dysfunction, affecting anti-tumor immunity. PPM1D, a phosphatase involved in DNA damage response, is degraded by proteasomes in a ubiquitination-independent manner, and its dysregulation is linked to cancer. Targeting negative regulators of degradation is a promising therapeutic strategy.
Immune Disorders and Antiviral Immunity
The E3 ligase ASB3 targets MAVS for ubiquitin-proteasomal degradation, downregulating antiviral innate immunity. Negative regulation of MAVS degradation by DUBs is critical for mounting effective antiviral responses. Dysregulation can lead to impaired immunity or autoimmune conditions.
Neurodegenerative Diseases
Impaired proteasomal degradation is a hallmark of neurodegenerative diseases such as Alzheimer's and Parkinson's, where protein aggregates accumulate. Negative regulation of this process may exacerbate or ameliorate aggregation, though specific mechanisms require further study.
Plant Stress and Hormone Signaling
In plants, negative regulation of proteasomal degradation modulates ABA signaling through AFP1 and PUB35, affecting stress responses and development. This highlights the evolutionary conservation of this regulatory mechanism.
From negative regulation of proteasomal protein catabolic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X negatively regulate proteasomal degradation of substrate Y? | Knockout cell line + proteasome inhibitor + western blot |
| What is the role of a specific phosphorylation site in regulating E3 ligase activity? | Point mutation knock-in |
| How does a disease-associated mutation affect substrate stability? | Knock-in of mutant allele |
| Where does the negative regulator localize and interact with the proteasome? | Tagged knock-in (e.g., GFP, HA) |
| Does overexpression of a DUB stabilize a target protein? | Overexpression cell line |
| Can CRISPR library screening identify novel negative regulators? | Genome-wide CRISPR knockout library + reporter |
How to Study the negative regulation of proteasomal protein catabolic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Ribo-seq | Translation efficiency and ribosome occupancy | Global effects on protein synthesis |
| RNA-seq | Transcriptional changes | Pathway analysis upon regulator knockout |
| Proteomics (MS) | Protein abundance and ubiquitination | Identify stabilized/destabilized substrates |
| CRISPR screen | Gene essentiality or reporter activation | Discover novel negative regulators |
| Western blot | Steady-state protein levels | Validate substrate stabilization |
| Immunoprecipitation | Protein-protein interactions | Map E3-substrate or DUB-substrate complexes |
| Proteasome activity assay | Catalytic activity of proteasome | Measure direct inhibition |
| Live-cell imaging | Real-time protein dynamics | Track degradation of fluorescent reporters |
Proteomics and Ubiquitinome Analysis
Mass spectrometry-based proteomics can quantify global protein stability and ubiquitination changes upon modulation of negative regulators. DiGly enrichment identifies ubiquitinated peptides, revealing substrates whose degradation is altered.
CRISPR Screening
Genome-wide CRISPR knockout or activation screens coupled with reporters for specific substrates can identify genes that negatively regulate proteasomal degradation. This approach has been used to discover regulators of immune signaling and apoptosis.
Imaging and Localization Studies
Fluorescence microscopy of tagged proteins (e.g., GFP) and proteasome markers can reveal colocalization and dynamics. Live-cell imaging assesses real-time degradation and the effect of negative regulators.
Biochemical Assays
In vitro ubiquitination and deubiquitination assays, proteasome activity assays, and immunoprecipitation can dissect molecular mechanisms. For example, PPM1D degradation was studied using cell-free systems.
How CRISPR Can Be Used to Study GO:1901799 negative regulation of proteasomal protein catabolic process
Knockout
CRISPR knockout of candidate negative regulators (e.g., DUBs, E3 ligases) can stabilize their substrates, leading to measurable phenotypic changes. For example, knocking out ASB3 would stabilize MAVS and enhance antiviral signaling. Knockout of KLHL6 may affect T cell function.
Point Mutation
Introducing point mutations in catalytic residues or regulatory phosphorylation sites of negative regulators can dissect their mechanism. For instance, mutating the catalytic cysteine of a DUB or the RING domain of an E3 ligase abolishes activity, revealing its role in substrate stabilization.
Knock-in
Knock-in of tagged versions (e.g., GFP, HA) allows visualization and immunoprecipitation of the regulator. Knock-in of disease-associated mutations can model their impact on proteasomal degradation.
Overexpression
Overexpression of a negative regulator can enhance substrate stabilization and phenocopy loss of degradation. This is useful for gain-of-function studies and for testing therapeutic hypotheses.
How EDITGENE Supports negative regulation of proteasomal protein catabolic process Research
Researchers studying negative regulation of proteasomal protein catabolic process-related genes often need to determine whether a candidate gene is causally involved in stabilizing or destabilizing specific substrates. EDITGENE provides comprehensive CRISPR services to accelerate this discovery.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of proteasomal protein catabolic process research.
Frequently Asked Questions About negative regulation of proteasomal protein catabolic process
What is GO:1901799?
GO:1901799 is a Gene Ontology term for negative regulation of proteasomal protein catabolic process, defined as any process that stops, prevents, or reduces the frequency, rate, or extent of proteasomal protein catabolic process.
What genes are involved in negative regulation of proteasomal protein catabolic process?
Key genes include KLHL6, MAVS, ASB3, PPM1D, ABI5, AFP1, PUB35, and various deubiquitinating enzymes and proteasome subunits.
How does negative regulation of proteasomal degradation affect cancer?
It can stabilize oncoproteins or destabilize tumor suppressors, promoting tumorigenesis; targeting these pathways is a therapeutic strategy.
What are the mechanisms of negative regulation of proteasomal protein catabolic process?
Mechanisms include deubiquitination of substrates, inhibition of proteasome activity, sequestration of substrates, and regulation of E3 ligase activity.
Which diseases are linked to dysregulation of proteasomal degradation?
Cancer, immune disorders, neurodegenerative diseases, and plant stress responses are linked to dysregulation of this process.
How can CRISPR be used to study negative regulation of proteasomal degradation?
CRISPR knockout, point mutation, knock-in, and overexpression models allow precise manipulation of candidate genes to assess their impact on substrate stability.
What is the role of deubiquitinating enzymes in GO:1901799?
DUBs remove ubiquitin chains from substrates, preventing their proteasomal degradation and thus negatively regulating the process.
Can proteasomal degradation occur without ubiquitination?
Yes, PPM1D is degraded by proteasomes in a ubiquitination-independent manner through its carboxyl-terminal region.
What model organisms are used to study negative regulation of proteasomal degradation?
Human cell lines, mice, fission yeast, and Arabidopsis are commonly used.
How does ASB3 regulate antiviral immunity?
ASB3 is an E3 ligase that targets MAVS for ubiquitin-proteasomal degradation, thereby downregulating antiviral innate immunity.
Conclusion
GO:1901799, negative regulation of proteasomal protein catabolic process, is a critical biological process that controls protein stability and cellular signaling. Its dysregulation contributes to cancer, immune disorders, and other diseases, making it a rich area for research. CRISPR-based models and advanced proteomics offer powerful tools to dissect its mechanisms and identify therapeutic targets.
References
- 1. Cheng H et al.. 2026. The ubiquitin ligase KLHL6 drives resistance to CD8(+) T cell dysfunction.. Nature 651(8105):451-461 PMID: 41535474
- 2. Budroni V et al.. 2021. Negative Regulation of the Innate Immune Response through Proteasomal Degradation and Deubiquitination.. Viruses 13(4) PMID: 33808506
- 3. Du C et al.. 2024. The U-box E3 ubiquitin ligase PUB35 negatively regulates ABA signaling through AFP1-mediated degradation of ABI5.. Plant Cell 36(9):3277-3297 PMID: 38924024
- 4. Takahashi M et al.. 2025. PPM1D is directly degraded by proteasomes in a ubiquitination-independent manner through its carboxyl-terminal region.. J Biomed Sci 32(1):88 PMID: 40931354
- 5. Cheng M et al.. 2024. The E3 ligase ASB3 downregulates antiviral innate immunity by targeting MAVS for ubiquitin-proteasomal degradation.. Cell Death Differ 31(12):1746-1760 PMID: 39266719
- 6. Amberg KL et al.. 2025. Proteasome regulation of petite-negativity in fission yeast.. BMC Biol 23(1):302 PMID: 41068765
- 7. Abbas R et al.. 2021. Killing by Degradation: Regulation of Apoptosis by the Ubiquitin-Proteasome-System.. Cells 10(12) PMID: 34943974
- 8. Mathien S et al.. 2021. Regulation of Mitogen-Activated Protein Kinase Signaling Pathways by the Ubiquitin-Proteasome System and Its Pharmacological Potential.. Pharmacol Rev 73(4):263-296 PMID: 34732541
